apratastat   Click here for help

GtoPdb Ligand ID: 6482

Synonyms: compound 5h [PMID: 16426848] | TMI-05 | TMI005
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Apratastat (TMI-005) is an orally active dual TACE (ADAM17)/MMP13 inhibitor that was developed for the potential treatment of inflammation [2]. TACE = TNF α-converting enzyme, which is a well validated therapeutic target for the treatment of rheumatoid arthritis. Inhibition of MMP13 (a peptidase that preferentially degrades type II collagen and aggrecan) is relevant since this is predicted to prevent the degradation of cartilage in rheumatoid arthritis [1,4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 149.85
Molecular weight 414.09
XLogP 0.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC#CCOc1ccc(cc1)S(=O)(=O)N1CCSC(C1C(=O)NO)(C)C
Isomeric SMILES OCC#CCOc1ccc(cc1)S(=O)(=O)N1CCSC([C@@H]1C(=O)NO)(C)C
InChI InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)/t15-/m0/s1
InChI Key MAVDNGWEBZTACC-HNNXBMFYSA-N
No information available.
Summary of Clinical Use Click here for help
Apratastat (TMI-005) was a rheumatoid arthritis clinical candidate. It completed Phase 2 clinical evaluation in trial NCT00095342.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00095342 Study Evaluating TMI-005 in Active Rheumatoid Arthritis Phase 2 Interventional Wyeth is now a wholly owned subsidiary of Pfizer